Andrew Kelly

4PUBLICATIONS
11CO-AUTHORS
Molecular targetsPredictive and prognostic markersTumour immunology
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (4)

|Jul 23, 2026
Acquired TSC1 Mutation as a Mechanism of Alectinib Resistance in ALK-Fused Leiomyosarcoma: Response to Combined ALK and Mammalian Target of Rapamycin Inhibition.

|Mar 09, 2022
Genome-wide DNA methylation patterns reveal clinically relevant predictive and prognostic subtypes in human osteosarcoma.

Christopher E Lietz, Erik T Newman, Andrew D Kelly

|Nov 24, 2021
Pan-cancer landscape of CD274 (PD-L1) rearrangements in 283,050 patient samples, its correlation with PD-L1 protein expression, and immunotherapy response.

Andrew D Kelly, Karthikeyan Murugesan, Zheng Kuang

|Aug 23, 2021
STRN-ALK Fusion-Positive Case of Breast Cancer With Response to Alectinib.

Andrew D Kelly, Tom Wiklund, Juha Kononen

Pageof 1

Frequent Collaborators

1 joint publications

Juha Kononen

1 joint publications

Karthikeyan Murugesan

1 joint publications

Richard S P Huang

1 joint publications

Christopher E Lietz